The global familial adenomatous polyposis treatment market is anticipated to grow at a significant CAGR of 13.9 % during the forecast period. According to the National Cancer Institute trial investigates on obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is a rare gene defect that increases the risk of developing cancer of the intestines and colon. OCA is a drug similar to bile acids, a fluid made and released by the liver. It binds to a receptor in the intestine that is believed to have a positive effect on preventing cancer development. Moreover, OCA has been effective in treating primary biliary cholangitis (PBC), a liver disease, and is approved by the Food and Drug Administration (FDA). There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.
Browse the full report description of “Global Familial Adenomatous Polyposis Treatment Market Size, Share, and Trends Analysis Report, By Type (Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, and Others), and By Application (Clinic, Hospital, and Others) for the Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/transdermal-patches-market
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Cancer Prevention Pharmaceuticals, Marina Biotech, Thetis Pharmaceuticals LLC, and others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Familial Adenomatous Polyposis Treatment Market
By Type
By Application
Global Familial Adenomatous Polyposis Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/familial-adenomatous-polyposis-treatment-market